Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Gains from Investment Securities (2020 - 2023)

Candel Therapeutics' Gains from Investment Securities history spans 4 years, with the latest figure at $1.6 million for Q4 2023.

  • For Q4 2023, Gains from Investment Securities rose 157.22% year-over-year to $1.6 million; the TTM value through Dec 2023 reached -$9.6 million, up 10.63%, while the annual FY2023 figure was $121000.0, 97.86% down from the prior year.
  • Gains from Investment Securities for Q4 2023 was $1.6 million at Candel Therapeutics, up from $1.3 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.5 million in Q1 2023 and bottomed at -$8.3 million in Q1 2022.
  • The 4-year median for Gains from Investment Securities is $1.3 million (2022), against an average of $993820.2.
  • The largest YoY upside for Gains from Investment Securities was 18922.07% in 2022 against a maximum downside of 3091.7% in 2022.
  • A 4-year view of Gains from Investment Securities shows it stood at $4.0 million in 2020, then increased by 19.19% to $4.8 million in 2021, then crashed by 157.37% to -$2.7 million in 2022, then surged by 157.22% to $1.6 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Gains from Investment Securities are $1.6 million (Q4 2023), $1.3 million (Q3 2023), and -$144000.0 (Q2 2023).